Kurve Therapeutics
Kurve Therapeutics is dedicated to developing innovative treatments for systemic and neurodegenerative disorders, aiming to improve quality of life and provide hope for patients with complex debilitating diseases. Their mission is to help as many people as possible through advanced medication and technology, with a focus on CNS disorders, Alzheimer's, Parkinson's, and other neurodegenerative conditions.
Industries
Nr. of Employees
small (1-50)
Kurve Therapeutics
16825 48th West, Suite 434, Lynnwood, WA 98037
Patents
Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
US-8001963-B2
View Details
Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
US-8001963-B2
View DetailsProducts
Intranasal delivery platform for CNS therapies
A device platform engineered to enhance nasal deposition and facilitate delivery of therapeutic agents to the brain via intranasal administration.
Preclinical cell-based oncolytic virus product (co-development)
A cell-based oncolytic virus therapeutic developed and tested in preclinical glioblastoma models demonstrating tumor reduction in vivo.
Intranasal formulation programs (CNS-focused)
Development and evidence generation for intranasal therapeutic formulations targeting cognitive and CNS outcomes, supported by peer‑reviewed studies.
Intranasal delivery platform for CNS therapies
A device platform engineered to enhance nasal deposition and facilitate delivery of therapeutic agents to the brain via intranasal administration.
Preclinical cell-based oncolytic virus product (co-development)
A cell-based oncolytic virus therapeutic developed and tested in preclinical glioblastoma models demonstrating tumor reduction in vivo.
Intranasal formulation programs (CNS-focused)
Development and evidence generation for intranasal therapeutic formulations targeting cognitive and CNS outcomes, supported by peer‑reviewed studies.
Services
Collaborative design and execution of clinical trials for intranasal device and formulation programs across Phase I–IIb with preparation for Phase III.
Preclinical efficacy testing and co-development for biologic and device-enabled therapeutics, including in vivo murine efficacy models and collaborative development pathways.
Facilitation of partnerships with academic institutions and support for peer‑reviewed publication of clinical and preclinical results.
Collaborative design and execution of clinical trials for intranasal device and formulation programs across Phase I–IIb with preparation for Phase III.
Preclinical efficacy testing and co-development for biologic and device-enabled therapeutics, including in vivo murine efficacy models and collaborative development pathways.
Facilitation of partnerships with academic institutions and support for peer‑reviewed publication of clinical and preclinical results.
Expertise Areas
- Intranasal drug delivery and nasal-to-brain targeting
- CNS-focused clinical trial management (Phase I–III)
- Formulation development for intranasal peptide/protein therapeutics
- Preclinical efficacy testing and multi‑species animal models
Key Technologies
- Intranasal delivery devices and fluid-dynamics‑based device design
- Intranasal peptide/protein formulation methods
- Controlled particle-dispersion and aerosolization techniques
- Scintigraphic deposition imaging and quantitative nasal deposition methods